journal
MENU ▼
Read by QxMD icon Read
search

Gastroenterology & Hepatology

journal
https://www.readbyqxmd.com/read/28035205/inhibition-of-interleukin-12-and-or-23-for-the-treatment-of-inflammatory-bowel-disease
#1
Sands Bruce E
No abstract text is available yet for this article.
December 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035204/esophageal-cancer-prevention
#2
K Wang Kenneth
No abstract text is available yet for this article.
December 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035203/the-possible-association-between-daa-treatment-for-hcv-infection-and-hcc-recurrence
#3
Brown Robert S
No abstract text is available yet for this article.
December 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035202/nonalcoholic-steatohepatitis-and-endpoints-in-clinical-trials
#4
William N Hannah, Dawn M Torres, Stephen A Harrison
Nonalcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in developed countries, and the rates of NAFLD continue to rise in conjunction with the obesity pandemic. While the majority of patients with isolated steatosis generally have a benign course, a diagnosis of nonalcoholic steatohepatitis (NASH) carries a significantly higher risk for progression of disease, cirrhosis, and death. Pharmacologic therapeutic interventions in NASH have largely proven to be ineffective or unappealing due to long-term side-effect profiles, and the majority of patients cannot achieve or sustain targeted weight loss goals, necessitating an urgent need for therapeutic trials and drug development...
December 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035201/the-role-of-biosimilars-in-inflammatory-bowel-disease
#5
Sudarshan Paramsothy, Noa Krugliak Cleveland, Nada Zmeter, David T Rubin
Monoclonal antibody biologic therapies, introduced nearly 20 years ago, revolutionized the treatment of inflammatory bowel disease (IBD) and are now well established as the most effective agents available. As the first of these biologic agents starts to come off patent, biosimilar agents have emerged as alternatives to originator drugs. The unique drug development and manufacturing processes involved in the creation of biologic agents pose distinct regulatory challenges compared to generic formulations of conventional medications...
December 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035200/volumetric-laser-endomicroscopy-in-patients-with-barrett-esophagus
#6
Herbert C Wolfsen
No abstract text is available yet for this article.
November 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035199/update-on-the-incidence-and-prevalence-of-inflammatory-bowel-disease-in-the-united-states
#7
Edward V Loftus
No abstract text is available yet for this article.
November 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035198/iron-overload-in-patients-with-chronic-liver-disease
#8
Kris V Kowdley
No abstract text is available yet for this article.
November 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035197/evolving-new-strategies-for-the-medical-management-of-chronic-hepatitis-b-virus-infection
#9
Timothy M Block, Tianlun Zhou, Nikhil Anbarasan, Robert Gish
Is a cure for chronic hepatitis B virus (HBV) infection possible? Hepatitis C virus infection is now routinely cured medically. There is a growing expectation that new drugs for the management of chronic HBV infection should provide substantial benefit over and above that of current chronic HBV medications, if not be curative. Although the definition of medically induced cure for chronic HBV infection varies, most include sustained off-drug absence of viremia and negativity for other virologic markers. There are currently more than 29 drugs in the pipeline being tested for the management of chronic HBV infection...
November 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28035196/therapeutic-use-of-cannabis-in-inflammatory-bowel-disease
#10
Waseem Ahmed, Seymour Katz
The marijuana plant Cannabis sativa and its derivatives, cannabinoids, have grown increasingly popular as a potential therapy for inflammatory bowel disease (IBD). Studies have shown that modulation of the endocannabinoid system, which regulates various functions in the body and has been shown to play a key role in the pathogenesis of IBD, has a therapeutic effect in mouse colitis. Epidemiologic data and human therapy studies reveal a possible role for cannabinoids in the symptomatic treatment of IBD, although it has yet to be determined in human populations whether cannabinoids have therapeutic anti-inflammatory effects in IBD or are simply masking its many debilitating symptoms...
November 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28070174/the-hcv-treatment-revolution-continues-resistance-considerations-pangenotypic-efficacy-and-advances-in-challenging-populations
#11
Ira M Jacobson
The US Food and Drug Administration has now approved 10 direct-acting antivirals (DAAs) for the management of hepatitis C virus (HCV). These therapies are combined into 6 regimens that are given for varying durations, with or without ribavirin, depending on the viral genotype, the presence or absence of baseline resistance-associated variants (RAVs), and the patient type. RAVs may be present before exposure to a drug or may become detectable de novo during exposure to a drug. Emerging resistant strains are the most common cause of failure of HCV DAA regimens...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917081/the-possible-association-between-proton-pump-inhibitors-and-dementia
#12
David A Johnson
No abstract text is available yet for this article.
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917080/endoscopic-management-of-perforations-in-the-gastrointestinal-tract
#13
Paul Fockens
No abstract text is available yet for this article.
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917079/stem-cell-therapy-for-perianal-fistulas-in-crohn-s-disease
#14
Julian Panes
No abstract text is available yet for this article.
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917078/global-elimination-of-hepatitis-c-virus
#15
John W Ward
No abstract text is available yet for this article.
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917077/the-role-of-liver-biopsy-in-hepatocellular-carcinoma
#16
Richard S Finn
No abstract text is available yet for this article.
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917076/the-cost-effectiveness-of-vedolizumab-for-inflammatory-bowel-disease-a-review-of-the-current-literature
#17
Yecheskel Schneider, Monica Saumoy, Shirley Cohen-Mekelburg, Adam F Steinlauf, Ellen J Scherl
The United States spends a greater share per gross domestic product on health care than any other developed country in the world. Cost-conscious, high-value care has an important role in the practice of medicine. Inflammatory bowel disease (IBD) affects 1.6 million people in the United States and is responsible for significant health care costs, with estimates as high as $31.6 billion annually, a large portion of which is attributable to the use of biologic therapies. As the number of therapeutic targets for IBD expands, gastroenterologists can anticipate the arrival of novel therapeutic agents on the market, and these may carry significant costs...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917075/management-of-clostridium-difficile-infection
#18
Layth S Al-Jashaami, Herbert L DuPont
Since the discovery of Clostridium difficile infection (CDI) in the 1970s, there has been an increase in the incidence, severity, and recurrence rate of the disease. We reviewed the recent CDI literature in PubMed published before February 28, 2016 that focused on advances in therapy. Despite a large number of studies describing methods for diagnosing the disease, there is currently no definitive test that identifies this infection with certainty, which complicates therapy. Recommended therapy for CDI includes oral metronidazole for mild cases and oral vancomycin or fidaxomicin for moderate to severe cases, each given for 10 to 14 days...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917074/medical-management-of-metabolic-complications-of-liver-transplant-recipients
#19
Abbey Barnard, Peter Konyn, Sammy Saab
Improved short- and long-term survival of liver transplant recipients has led to increased focus on complications of both the early and late posttransplant periods. A variety of metabolic complications have been observed in the post-orthotopic liver transplant population, including hypertension, hyperlipidemia, obesity, diabetes mellitus, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis. Although only a small proportion of patients experience metabolic complications prior to transplantation, the prevalence of these complications posttransplantation reaches or exceeds that of the general population...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27917073/clostridium-difficile-infection
#20
Gary R Lichtenstein
No abstract text is available yet for this article.
October 2016: Gastroenterology & Hepatology
journal
journal
41233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"